Arcuro Medical

Market position

Arcuro positions SuperBall within sports medicine markets driven by trends toward meniscal preservation and rotator cuff augmentation, targeting a population of over two million meniscus surgeries per year of which historically fewer than 25% are repaired rather than resected.

The system uses soft, flexible all-suture bundles in place of hard polymer implants, a knotless extracapsular fixation that leaves no knots in the joint space, a tensioning mechanism giving surgeons control comparable to inside-out repair, and a proprietary mesh construct that lays flat to limit tissue damage to the meniscus and articulating cartilage.

Technology

SuperBall is an all-inside, all-suture, knotless soft-tissue repair platform combining suture bundles, a proprietary flat-laying repair suture mesh, a controlled tensioning mechanism and extracapsular fixation. Applications include meniscal repair and, via SuperBall-RC, rotator cuff repair. The technology holds U.S. FDA 510(k) clearance, a CE mark and ISO 13845 certification, and is covered by patents in the U.S., China and Europe.

Go-to-market

Arcuro sells through a U.S. sales organization built out in 2024 alongside a worldwide distribution network of U.S. and international partners, supported by clinical and biomechanical evidence generation aimed at surgeon adoption.

Orthopedic and sports medicine surgeons performing meniscal and rotator cuff repair procedures, and the hospitals and surgical facilities where those procedures take place.

Geography

Headquarters and R&D in Misgav Business Park, Misgav, Israel, with U.S. entities and operations in Bethlehem, Pennsylvania; Naples, Florida; and Minneapolis, Minnesota, plus international distribution partners serving markets outside the U.S.

History

The company was founded in 2013 (an investor profile lists incorporation in December 2013; the company's own site cites 2014) by executives with combined experience in developing and manufacturing minimally invasive orthopedic products. Co-founder Lee Ranon served as CEO through the transition from early R&D into commercialization. SuperBall cases began accumulating from 2020, and in May 2024 MedTech executive Jamal Rushdy, previously an Arcuro board member and adviser, was appointed CEO, with Ranon moving to Chief Operating Officer – Israel, overseeing R&D, regulatory and quality, and Israeli operations. In 2024 the company established a new U.S. organization, hired sales leadership, added U.S. and international distribution partners, submitted a 510(k) for a new product line, and surpassed 5,000 global SuperBall cases. In January 2025 it announced the initial closing of a Series A round led by Varana Capital.